Latest news

Exercise of Options and TVR

13 May 2021

Half-year Report

23 April 2021

Research Update

25 March 2021

Interim Results Extension

25 March 2021

RSS Icon

Find out more


The potential of Sareum's SDC-1801 TYK2/JAK1 inhibitor in the fight against Covid-19

Find out more large-arrow.png


Sareum has an innovative pipeline of drug development candidates.

Find out more large-arrow.png


IMC Half Year Results, Apr 2021 (Slides)
LSX World Congress, Feb 2021 (Video)
IMC Full Year Results, Oct 2020 (Slides)
Proactive Investors, Aug 2020 (Video)

  • @Sareumplc Latest tweet

    "TYK2 has emerged as a target of choice for the treatment of autoimmune diseases and severe COVID-19 with an optimu… via @Sareumplc
    View more